Eugene Shenderov

May 31, 2023 | urotoday.com | Eugene Shenderov

Read the Full Video TranscriptAndrea Miyahira: Welcome, everyone. I'm Andrea Miyahira, the Senior Director of Global Research and Scientific Communications at PCF. Today I'm joined by Dr. Eugene Shenderov, an assistant professor at Johns Hopkins. Dr. Shenderov team have recently published a paper, Neoadjuvant Enoblituzumab in Localized Prostate Cancer: A Single-Arm, Phase II Trial in Nature Medicine. Eugene, thanks for joining us today. Eugene Shenderov: It is my pleasure to be here.

May 31, 2023 | urotoday.com | Eugene Shenderov

In a conversation with Andrea Miyahira, Eugene Shenderov discusses the recent study conducted by his team and published under the title, “Neoadjuvant Enoblituzumab in Localized Prostate Cancer: A Single-Arm, Phase II Trial.” In the past, immunotherapies have demonstrated limited efficacy in prostate cancer treatment. This is primarily due to the necessity for selective immunotherapy in this setting, as current checkpoint blockades such as PD-1 and CTLA-4 have shown only modest activity.

Apr 3, 2023 | nature.com | Eugene Shenderov |Tamara L. Lotan |Hao Wang |Hongkai Ji |Sarah Church |Paul Fields | +1 more

Author notesEmmanuel S. AntonarakisPresent address: University of Minnesota Masonic Cancer Center, Minneapolis, MN, USAAuthors and AffiliationsDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USAEugene Shenderov, Angelo M. De Marzo, Tamara L. Lotan, Sin Chan, Carolyn Chapman, Samuel R. Denmeade, Kenneth J. Pienta, Drew M. Pardoll & Emmanuel S.